title: Anti-cancer Activities of Ginseng Extract Fermented with Phellinus linteus.
abstract: In the present study, the anti-cancer effects of ginseng fermented with Phellinus linteus (GFPL) extract were examined through in vitro and in vivo assays. GFPL was produced by co-cultivating ginseng and Phellinus linteus together. Ginsenoside Rg3, Rh1 and Rh2 are important mediators of anti-angiogenesis and their levels in GFPL were enriched 24, 19 and 16 times, respectively, more than that of ginseng itself through the fermentation. GFPL exhibited distinct anti-cancer effects, including growth inhibition of the human lung carcinoma cell line A549, and promotion of immune activation by stimulating nitric oxide (NO) production in Raw 264.7 cells. Further evidence supporting anti-cancer effects of GFPL was its significant prolongment of the survival of B16F10 cancer cell-implanted mice. These results suggest that the GFPL may be a candidate for cancer prevention and treatment through immune activation and anti-angiogenic effects by enriching Rg3, Rh1 and Rh2.
authors: Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd., Suwon 443-766, Korea.
authors: Jong-Jin
authors: JJ
authors: Lee
authors: Ho-Kyun
authors: HK
authors: Kwon
authors: In-Ho
authors: IH
authors: Jung
authors: Yong-Baik
authors: YB
authors: Cho
authors: Kyu-Joong
authors: KJ
authors: Kim
authors: Jong-Lae
authors: JL
authors: Kim
keywords: Antitumor activity; Ginsenoside Rg3; HUVEC; Phellinus linteus
references: Free Radic Biol Med. 1999 Apr;26(7-8):925-35
references: 10232836
references: J Investig Dermatol Symp Proc. 2000 Dec;5(1):40-6
references: 11147674
references: Am Fam Physician. 2003 Oct 15;68(8):1539-42
references: 14596440
references: Zhonghua Fu Chan Ke Za Zhi. 2002 Apr;37(4):227-30
references: 12133417
references: Nat Med. 1995 Jan;1(1):27-31
references: 7584949
references: J Korean Med Sci. 2001 Dec;16 Suppl:S6-18
references: 11748383
references: Biochem Pharmacol. 2001 Feb 1;61(3):253-70
references: 11172729
references: Ann Intern Med. 1994 Feb 1;120(3):227-37
references: 8273987
references: Yakugaku Zasshi. 2005 Jul;125(7):587-91
references: 15997216
references: J Neurosci Res. 1998 Aug 15;53(4):426-32
references: 9710262
references: Mycobiology. 2006 Sep;34(3):143-7
references: 24039488
references: Biol Pharm Bull. 1995 Sep;18(9):1197-202
references: 8845804
references: J Biol Chem. 1993 Jan 25;268(3):1908-13
references: 7678412
references: Eur J Pharmacol. 1998 Jan 12;341(2-3):139-44
references: 9543231
references: Yao Xue Xue Bao. 1995;30(9):674-8
references: 8701743
references: Arch Biochem Biophys. 2002 Oct 1;406(1):1-8
references: 12234484
references: Cancer Lett. 2005 Jan 31;218(1):43-52
references: 15639339
references: Biochem Pharmacol. 2006 Aug 14;72(4):437-45
references: 16793023
references: J Immunol. 1992 Sep 15;149(6):2114-22
references: 1325525
references: Lab Invest. 1992 Oct;67(4):519-28
references: 1279270
references: Trends Pharmacol Sci. 2002 Dec;23(12):576-82
references: 12457776
references: J Exp Med. 1989 May 1;169(5):1543-55
references: 2497225
references: Immunopharmacology. 1999 Feb;41(2):157-64
references: 10102797
references: Cancer Treat Res. 2004;117:307-36
references: 15015567
references: Pharmacol Rev. 1991 Jun;43(2):109-42
references: 1852778
references: Adv Cancer Res. 1974;19(0):331-58
references: 4605404